An Automated Assay for Growth Differentiation Factor 15

Wollert, Kai C.; Kempf, Tibor; Giannitsis, Evangelos; Bertsch, Thomas; Braun, Siegmund; Maier, H.; Reim, Manfred; Christenson, Robert H.

doi:10.1373/jalm.2016.022376

Cited by 36 publications

(29 citation statements)

References 30 publications

(58 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Plasma GDF-15 was measured by a different method in the healthy control group. There has however been published a study that compares different methods to measure GDF-15, and it shows a good correlation between the two methods [18]. We are therefore confident that the comparison is reliable.…”

Section: Discussionmentioning

confidence: 71%

See 1 more Smart Citation

Growth Differentiation Factor 15 in Children with Chronic Kidney Disease and after Renal Transplantation

et al. 2020

View full text Add to dashboard Cite

Growth differentiation factor 15 (GDF-15) is strongly associated with cardiovascular disease (CVD). The aim of our study was to evaluate plasma and urinary levels of GDF-15 after pediatric renal transplantation (Rtx) and in children with chronic kidney disease (CKD) and its associations to cardiovascular risk factors. In this cross-sectional study, GDF-15 was measured in plasma and urine from 53 children with a renal transplant and 83 children with CKD and related to cardiovascular risk factors (hypertension, obesity, and cholesterol) and kidney function. Forty healthy children served as a control group. Plasma levels of GDF-15 (median and range) for a Tx (transplantation) cohort, CKD cohort, and healthy controls were, respectively, 865 ng/L (463-3039 ng/L), 508 ng/L (183-3279 ng/L), and 390 ng/L (306-657 ng/L). The CKD and Tx cohorts both had significantly higher GDF-15 levels than the control group (p<0.001). Univariate associations between GDF-15 and hyperuricemia (p<0.001), elevated triglycerides (p=0.028), low HDL (p=0.038), and obesity (p=0.028) were found. However, mGFR (p<0.001) and hemoglobin (p<0.001) were the only significant predictors of GDF-15 in an adjusted analysis. Urinary GDF-15/creatinine ratios were 448 ng/mmol (74–5013 ng/mmol) and 540 ng/mmol (5–14960 ng/mmol) in the Tx cohort and CKD cohort, respectively. In the CKD cohort, it was weakly correlated to mGFR (r=−0.343, p=0.002). Plasma levels of GDF-15 are elevated in children with CKD and after Rtx. The levels were not associated with traditional cardiovascular risk factors but strongly associated with renal function.

show abstract

Section: Discussionmentioning

confidence: 71%

“…According to a recent study [18], there is a good correlation between the two different methods of measuring GDF-15 in plasma.…”

Section: Bloodmentioning

confidence: 98%

Growth Differentiation Factor 15 in Children with Chronic Kidney Disease and after Renal Transplantation

et al. 2020

View full text Add to dashboard Cite

show abstract

“…GDF‐15 levels appear somewhat lower than plasma concentrations of apparently healthy individuals determined by IRMA or the Roche assay in other studies, which may be based on the nature of a manual technique or that the ELISA method seems to results in lowest GDF‐15 values compared to IRMA or the Elecsys® measurements . Altogether a very good correlation was shown for the ELISA method with the just recently available first clinically approved Elecsys® assay (Roche Diagnostics) …”

Section: Discussionmentioning

confidence: 99%

“…levels with all-cause mortality in unselected treatment-naïve cancer patients according to tumour site (n = 555) or the Elecsys® measurements. 23 Altogether a very good correlation was shown for the ELISA method with the just recently available first clinically approved Elecsys® assay (Roche Diagnostics). 23…”

Section: T a B L E 3 Association Of Gdf-15mentioning

confidence: 99%

GDF‐15 in solid vs non‐solid treatment‐naïve malignancies

Arfsten

Cho

Freitag

et al. 2019

Eur J Clin Investigation

View full text Add to dashboard Cite

AimGDF‐15 is an established cardiovascular risk marker but is equally implicated in tumour biology. Elevated levels of GDF‐15 have indeed been observed in distinct tumour entities. This study aimed to explore the relation of GDF‐15 to other cardiac biomarkers and the general association of GDF‐15 on prognosis in an unselected cohort of treatment‐naïve cancer patients.MethodsWe prospectively enrolled 555 consecutive patients at time of diagnosis of malignant disease prior receiving anticancer therapy. Plasma GDF‐15 concentrations were determined alongside other cardiac and routine laboratory markers. All‐cause mortality was defined as primary endpoint.ResultsGDF‐15 levels were 338 ng/L (IQR:205‐534) for the total cohort, and values were comparable for different tumour entities except breast cancer. Metastatic disease was characterized by higher plasma GDF‐15 [435 ng/L (IQR:279‐614) vs 266 ng/L (IQR:175‐427), P < .001]. GDF‐15 correlated positively with inflammatory status reflected by CRP, SAA and IL‐6 [r = .31, P < .001, r = .23, P < .001 and r = .14, P = .002] and cardiac biomarkers as NT‐proBNP, hsTnT, MR‐proADM and CT‐proET‐1 [r = .46; r = .46; r = .59 and r = .50; P < .001 for all]. GDF‐15 was significantly associated with all‐cause mortality after multivariate adjustment [adj.HR for ln(GDF‐15) 1.78, 95%CI:1.47‐2.16, P < .001]. There was a significant interaction between solid and haematological malignancies with loss of association of GDF‐15 with outcome in myelodysplastic and myeloproliferative disease.ConclusionsElevated plasma GDF‐15 is associated with progressing disease severity and poor prognosis in solid tumours of treatment‐naïve cancer patients. GDF‐15 increase is accompanied by worsening systemic inflammation and a subclinical functional impairment of different organs including the heart. GDF‐15 represents a promising target for our pathophysiologic understanding in cardio‐oncology linking conditions of both cardiac and neoplastic disease.

show abstract

“…Czynniki wpływające na stężenie czynnika różnicowania wzrostu 15 (GDF-15, growth differentiation factor 15) i potencjalny wpływ tego biomarkera na mięsień sercowy (na podstawie [14,15] umożliwiła zautomatyzowanie oznaczania GDF-15, a tym samym jego szersze wykorzystanie [17]. Przeważająca liczba dotychczasowych badań wskazuje na trzy przedziały ryzyka sercowo-naczyniowego: stężenia poniżej 1200 ng/l odpowiadają niskiemu ryzyku (górna granica wartości referencyjnych dla osób zdrowych), 1200-1800 ng/lumiarkowanemu (przeciętnemu) ryzyku, a przekraczające 1800 ng/l -wysokiemu ryzyku [18].…”

Section: Znaczenie Biologiczne Gdf-15unclassified

Czynnik różnicowania wzrostu 15 jako biomarker w niewydolności serca

Piechota

Krzesiński

2018

Folia Cardiologica

View full text Add to dashboard Cite

An Automated Assay for Growth Differentiation Factor 15

Cited by 36 publications

References 30 publications

Growth Differentiation Factor 15 in Children with Chronic Kidney Disease and after Renal Transplantation

Growth Differentiation Factor 15 in Children with Chronic Kidney Disease and after Renal Transplantation

GDF‐15 in solid vs non‐solid treatment‐naïve malignancies

Czynnik różnicowania wzrostu 15 jako biomarker w niewydolności serca

Contact Info

Product

Resources

About